New Two-Pronged attack tested for Tough-to-Treat skin cancer
NCT ID NCT06984328
Summary
This study is testing whether a new drug called acasunlimab works better alone or combined with an existing cancer drug (pembrolizumab) for people with advanced skin melanoma that has continued to grow despite prior immunotherapy. All participants will receive active treatment—no one gets a placebo. The main goal is to see if the treatment shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pan American Center for Oncology Trials, LLC
San Juan, 00909, Puerto Rico
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.